FISHERS, Ind. July 25: Bangs Laboratories, Inc. today announced that it will introduce UltraMod™, its next-generation microsphere platform, in a dedicated lecture session at the Association for Diagnostics & Laboratory Medicine (ADLM) 2026 Annual Meeting (Tuesday 7-28/ 12:30pm Exhibit Hall Theater 2). The session, part of the ADLM Lecture Series, is titled "Engineering a Better Bead: Introducing UltraMod™ Technology for Accelerated Development, Scaling, and Validation of Fit-for-Purpose Microspheres."
UltraMod™ is designed to address a persistent challenge in diagnostic assay development: the time and variability associated with optimizing bead-based reagents for specific clinical and laboratory applications. The platform's modular development workflow allows developers to systematically fine-tune key microsphere attributes — including magnetic separation speed, surface characteristics, and particle size — while preserving lot-to-lot consistency.
"Bead-based assays are only as good as the beads behind them," said Kathy Kilbride, Senior Director of Technical Discovery, Bangs Laboratories. "UltraMod™ was built to give assay developers a more predictable, modular path from early-stage optimization through scale-up and validation, so teams can spend less time troubleshooting reagents and more time advancing their assays."
Session Details
During the presentation, attendees will:
- Explore case studies demonstrating how UltraMod's™ modular design principles can be applied to ongoing reagent development efforts.
- Learn how UltraMod's™ scaling strategies can be integrated into existing workflows to reduce optimization cycles and shorten assay validation timelines.
- Review a validation framework aligned with regulatory expectations, to support informed selection of bead-based reagent platforms.
The session is designed for assay developers, laboratory scientists, and diagnostics R&D professionals, and is presented at an intermediate level. Attendees will leave with practical strategies for compressing development timelines, reducing reagent variability, and supporting robust assay validation across both laboratory and clinical diagnostic settings.
